X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Allocetr-OTS is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state in patients with moderate to severe knee osteoarthritis.
Lead Product(s): Allocetra-OTS
Therapeutic Area: Musculoskeletal Product Name: Allocetra-OTS
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. It is under phase 1/2 clinical development for the treatment of moderate to severe knee osteoarthritis.
Lead Product(s): Allocetra-OTS
Therapeutic Area: Musculoskeletal Product Name: Allocetra-OTS
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Allocetra™ is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, demostrated positive results in patients with sepsis associated with pneumonia, biliary, urinary tract, or peritoneal infections.
Lead Product(s): Allocetra-OTS
Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells. It is under phase 2 clinical trials for sepsis associated with pneumonia, biliary, urinary tract, or peritoneal infections.
Lead Product(s): Allocetra-OTS
Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. It is under phase 1/2 clinical development for the treatment of moderate to severe knee osteoarthritis.
Lead Product(s): Allocetra-OTS
Therapeutic Area: Musculoskeletal Product Name: Allocetra-OTS
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells. It is under phase 2 clinical trials for sepsis associated with pneumonia, biliary, urinary tract, or peritoneal infections.
Lead Product(s): Allocetra-OTS
Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Drug has the potential to provide a novel immunotherapeutic action for life-threatening indications such as solid cancers, sepsis etc.
Lead Product(s): Allocetra-OTS
Therapeutic Area: Infections and Infectious Diseases Product Name: Allocetra-OTS
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Allocetra-OTS is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Drug has the potential to provide a novel immunotherapeutic action for life-threatening indications such as solid cancers, sepsis etc.
Lead Product(s): Allocetra-OTS,Undisclosed
Therapeutic Area: Oncology Product Name: Allocetra
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
Allocetra-OTS is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Drug has the potential to provide a novel immunotherapeutic action for life-threatening indications such as solid cancers, sepsis etc.
Lead Product(s): Allocetra-OTS,CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Allocetra-OTS
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
The collaboration aims to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors.
Lead Product(s): Allocetra-OTS,Tislelizumab
Therapeutic Area: Oncology Product Name: Allocetra-OTS
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
